Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35518 SUPERNUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) | Delaware | | ...

Financial Data and Key Metrics Changes - Total revenue for Q2 2023 was $135.5 million, down from $170.1 million in the same quarter last year, with net product sales of $128.3 million and royalty revenue of $7.2 million [41][42] - The decrease in net product sales was primarily due to a $52.3 million decline in Trokendi XR, partially offset by a $24 million increase in net sales from growth products Qelbree and GOCOVRI [42][43] - GAAP net loss for Q2 2023 was $800,000, or loss per diluted share of $0.02, compared to GAAP net earnings of $7.9 million, or earnings per diluted share of $0.14 in the same period last year [45] - For the first half of 2023, total revenue was $289.3 million, down from $322.6 million in the same period last year, with a similar trend in net product sales [46][47] Business Line Data and Key Metrics Changes - Qelbree and GOCOVRI achieved combined net sales of $60 million in Q2 2023, representing a 67% growth compared to the same period last year [13] - Qelbree's prescriptions grew by 9% in Q2 2023, reaching an all-time high of 146,344 quarterly prescriptions, which is a 133% increase compared to Q2 2022 [15][16] - GOCOVRI's net product sales increased to $29 million in Q2 2023, a 17% increase over the same period in 2022 [34] - Oxtellar XR net product sales were $24 million, down from $30 million in the same period last year, primarily due to destocking by wholesalers [35] Market Data and Key Metrics Changes - The ADHD market was essentially flat in Q2 2023 compared to Q1 2023, while Qelbree's prescriptions showed significant growth [15] - The adult segment for Qelbree grew by approximately 16%, while the pediatric segment grew by 5%-6% [23] - Pharmacy orders from wholesalers have significantly increased in early August, indicating a positive trend ahead of the back-to-school season [17] Company Strategy and Development Direction - The company is focused on making the 2023 transition smooth while moving away from legacy products and setting the stage for growth in 2024 and beyond [3] - The company plans to host an R&D Day on October 18, 2023, to provide insights into its product pipeline, emphasizing SPN-817 and SPN-820 [37][38] - The company continues to prioritize commercial assets for business development while remaining open to pipeline assets that could be launched in the near future [75][76] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of Qelbree, citing its unique clinical profile and increasing adoption among physicians [33][85] - The company expects sales to continue to grow in Q3 and Q4, driven by the back-to-school season [63] - Management noted that the stimulant shortages may not significantly benefit Qelbree, as physicians may opt for alternative stimulants rather than switching to non-stimulants [91] Other Important Information - The company had approximately $189.1 million in cash and marketable securities as of June 30, 2023, down from $555.2 million at the end of 2022, primarily due to the repayment of convertible senior notes [51][52] - The company reiterated its financial guidance for total revenue in 2023, expecting it to range from $580 million to $620 million [53] Q&A Session Summary Question: Can you comment on Qelbree's net price and any inventory fluctuations in Q2? - Management indicated that orders from pharmacies are showing a healthy increase, which is a positive leading indicator for future sales [58] Question: How does the sales trajectory for Qelbree look for Q3 and Q4? - Management expects prescriptions to pick up in Q3 and continue growing into Q4 due to the back-to-school season [63] Question: What are the underlying volume trends for GOCOVRI? - Management estimated prescription growth for GOCOVRI to be around 6% in the first half of the year, indicating healthy growth [73] Question: What is the company's strategy regarding business development? - The company continues to prioritize commercial assets while also considering pipeline assets that could be launched in the near future [75] Question: Can you explain the rationale behind the recent settlement regarding Oxtellar XR? - Management decided to settle to mitigate risks and allocate resources more effectively towards key brands like Qelbree and GOCOVRI [78]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35518 SUPERNUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) | Delaware | | | 20- ...

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Peter Vozzo - ICR Westwicke, IR Jack Khattar - CEO Tim Dec - CFO Conference Call Participants Andrew Tsai - Jefferies David Amsellem - Piper Sandler Jack Padovano - Stifel Operator Good afternoon, and welcome to Supernus Pharmaceuticals First Quarter 2023 Financial Results Conference Call. At this time all participants are in a listen-only mode. Later we will conduct a question-and-answer ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35518 SUPERNUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) | Delaware | | | 20 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 31, 2022 or ☐ TRANSMISSION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 001-35518 (Address of Principal Executive Offices) (zip code) (301) 838-2500 (Registrant's telephone number, including area cod ...

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET Company Participants Peter Vozzo - ICR Westwicke, IR Jack Khattar - CEO Tim Dec - CFO Conference Call Participants David Amsellem - Piper Sandler Andrew Tsai - Jefferies Jack Padovano - Stifel Operator Good afternoon, and welcome to Supernus Pharmaceuticals Fourth Quarter and Full Year 2022 Financial Results Conference Call. At this time all participants are in a listen-only mode. Later we will conduct ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35518 SUPERNUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) | Delaware | | ...

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Peter Vozzo - ICR Westwicke, Investor Relations Jack Khattar - Chief Executive Officer Tim Dec - Chief Financial Officer Conference Call Participants David Amsellem - Piper Sandler Jack Padovano - Stifel Operator Good afternoon and welcome to Supernus Pharmaceuticals' Third Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. [Ope ...

| --- | --- | |------------------------------------------------------------|-------| | | | | Supernus Pharmaceuticals | | | Corporate Overview September 2022 | | | © 2022 Supernus Pharmaceuticals, Inc. All Rights Reserved. | | 1 Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include forward-looking statements within the meaning of the federal securities laws. These statements, among other things, relate to Supernus' business strategy ...